Clinical Trial Update: Open-Label Extension of Other SZ1839 (Iressa) Trials [Phase 3]

View source ↗

Summary

Open-label extension updates for SZ1839 (Iressa) Phase 3 cancer trials have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Cancer | Phase 3 | Status: COMPLETED